Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent

被引：0
作者：
Buisson, A. [1 ]
Nachury, M. [2 ]
Fumery, M. [3 ]
Guilmoteau, T. [1 ]
Leclerc, E. [1 ]
Altwegg, R. [4 ]
Serrero, M. [5 ]
Mathieu, N. [6 ]
Treton, X. [7 ]
Vuitton, L. [8 ]
Pereira, B. [9 ]
Amiot, A. [10 ]
Bouguen, G. [11 ]
机构：
[1] Univ Hosp Estaing, Dept Gastroenterol, IBD Unit, Clermont Ferrand, France
[2] CHRU Lille, IBD Unit, Lille, France
[3] CHU Amiens, IBD Unit, Amiens, France
[4] CHU Montpellier, IBD Unit, Montpellier, France
[5] AP HM, IBD Unit, Marseille, France
[6] CHU Grenoble, IBD Unit, Grenoble, France
[7] AP HP Beaujon Hosp, IBD Unit, Paris, France
[8] CHU Besancon, IBD Unit, Besancon, France
[9] Univ Hosp Estaing, DRCI Biostat Unit, Clermont Ferrand, France
[10] AP HP Creteil Hosp, IBD Unit, Paris, France
[11] CHU Rennes, IBD Unit, Rennes, France
来源：
JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP76
引用
收藏
页码：I120 / I120
页数：1
相关论文
共 50 条
  • [21] Does Failure to Respond to One Anti-TNF Agent in Ulcerative Colitis Predict Treatment Failure With Other Anti-TNF Agents
    AlAlawi, Fatema
    Keegan, Denise
    Byrne, Kathryn
    Mulcahy, Hugh
    Cullen, Garret
    Doherty, Glen A.
    GASTROENTEROLOGY, 2015, 148 (04) : S266 - S267
  • [22] Real-World Evidence on the Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis in Lebanon
    Sharara, Ala I.
    Alrazim, Ayman
    Saniour, Philippe
    Daniel, Fady
    Rached, Antoine Abou
    Bahr, Abbas
    Azar, Cecilio
    Geagea, Antoine
    Ghoubar, Marcelle
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S) : S858 - S859
  • [23] Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis
    Lair-Mehiri, Loriane
    Stefanescu, Carmen
    Vaysse, Thibaut
    Laharie, David
    Roblin, Xavier
    Rosa, Isabelle
    Treton, Xavier
    Abitbol, Vered
    Amiot, Aurelien
    Bouguen, Guillaume
    Dib, Nina
    Fumery, Mathurin
    Pariente, Benjamin
    Carbonnel, Franck
    Peyrin-Biroulet, Laurent
    Simon, Marion
    Viennot, Stephanie
    Bouhnik, Yoram
    DIGESTIVE AND LIVER DISEASE, 2020, 52 (03) : 268 - 273
  • [24] Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study
    Hupe, M.
    Streichenberger, A.
    Wils, P.
    Arab, N.
    Serrero, M.
    Amiot, A.
    Bozon, A.
    Vuitton, L.
    Fumery, M.
    Altwegg, R.
    Nachury, M.
    Hebuterne, X.
    Yzet, C.
    Coban, D.
    Dodel, M.
    Bazoge, M.
    Pereira, B.
    Buisson, A.
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (08) : 1312 - 1318
  • [25] The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study
    Ye, Byong Duk
    Cheon, Jae Hee
    Song, Ki Hwan
    Kim, Joo Sung
    Kim, Young-Ho
    Yoon, Hyuk
    Lee, Kang-Moon
    Kang, Sang-Bum
    Jang, Byung Ik
    Park, Jae Jun
    Kim, Tae Oh
    Lee, Dae-Wook
    Foo, Chee Yoong
    Shin, Jeong Eun
    Park, Dong Il
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
  • [26] Does The Sequence Matter ? Comparative effectiveness of a second line biologic in patients with Ulcerative Colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab
    Miller, C.
    Kwok, H.
    Parisi, I.
    Harrow, P.
    McCartney, S.
    Vega, R.
    Rahman, F.
    Seward, E.
    Mehta, S.
    Lim, S.
    Sharma, E.
    Samaan, M.
    Bancil, A.
    Kok, K.
    Shalabi, A.
    Johnston, E.
    Katarey, D.
    Taherzadeh, N.
    Murray, C.
    Sharip, M.
    Carter, M.
    Radhakrishnan, S.
    Peake, S.
    Khakoo, I.
    Wahed, M.
    Povlsen, S.
    Patel, M.
    Dubois, P.
    Finkel, J.
    Onnie, C.
    Bloom, S.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S443 - S444
  • [27] A REAL-WORLD COMPARISON OF THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND ANTI-TNF THERAPIES IN EARLY TREATMENT INITIATION WITH FIRST-LINE BIOLOGIC THERAPY IN ULCERATIVE COLITIS: RESULTS FROM EVOLVE
    Mantzaris, Gerassimos J.
    Bressler, Brian
    Kopylov, Uri
    Bassel, Marielle
    Brett, Neil R.
    Colby, Chris
    Lopez, Claudia
    Saha, Sumit
    Kifnidi, Christina
    Agboton, Christian
    Adsul, Shashi
    Demuth, Dirk
    Luo, Michelle
    Wang, Song
    Yarur, Andres J.
    GASTROENTEROLOGY, 2020, 158 (06) : S405 - S405
  • [28] EFFICACY AND SAFETY OF TOFACITINIB AFTER FAILURE OF ANTI-TNF AGENT IN PATIENTS WITH ULCERATIVE COLITIS: A US-BASED PROPENSITY MATCHED COHORT STUDY
    Kochhar, Gursimran S.
    Desai, Aakash
    Dulai, Parambir S.
    Cross, Raymond K.
    Farraye, Francis A.
    Regueiro, Miguel D.
    El-Hachem, Sandra
    GASTROENTEROLOGY, 2023, 164 (06) : S646 - S647
  • [29] A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in ulcerative colitis: Results from EVOLVE
    Mantzaris, G.
    Bressler, B.
    Kopylov, U.
    Bassel, M.
    Brett, N.
    Colby, C.
    Lopez, C.
    Saha, S.
    Kifnidi, C.
    Agboton, C.
    Adsul, S.
    Demuth, D.
    Luo, M.
    Wang, S.
    Yarur, A.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S092 - S094
  • [30] Real-world evidence comparison on the effectiveness of ustekinumab vs anti-TNF or vedolizumab in ulcerative colitis: induction phase results from the prospective, observational RUN-UC study
    Bokemeyer, B.
    Plachta-Danielzek, S.
    Howaldt, S.
    Mohl, W.
    Efken, P.
    Ehehalt, R.
    Kahl, M.
    Krause, T.
    Trentmann, L.
    Luegering, A.
    Schnoy, E.
    Jochum, C.
    Salmon, S. Fajardo
    Hartmann, P.
    Gilman, E.
    Schreiber, S.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 872 - 872
12345